LEOPARD: The Lived Experience of Participants in an African Randomised Trial

Sponsor
London School of Hygiene and Tropical Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT04296292
Collaborator
Botswana Harvard AIDS Institute Partnership (Other), Infectious Diseases Institute, Uganda (Other), University of Zimbabwe (Other)
89
3
16.2
29.7
1.8

Study Details

Study Description

Brief Summary

There has been no previous qualitative study conducted in a low-income setting which has aimed to explore the experience of individuals who enrol into a clinical trial for the management of a life-threatening illness. The investigators plan to collect data from trial participants, their next-of-kin, and researchers working on a multi-site randomised controlled trial for the treatment of HIV-associated cryptococcal meningitis.

Condition or Disease Intervention/Treatment Phase
  • Other: In-depth interviews

Detailed Description

Individuals recruited into clinical trials for life-threatening illnesses are particularly vulnerable and this is especially true in low-income settings. The decision to enrol may be influenced by existing inequalities, a poor healthcare infrastructure and the fear of death. Where patients are confused or unconscious the responsibility for this decision falls on the relatives. The objectives of this study are to learn from the experience of participants, relatives and researchers involved in a randomised controlled trial, AMBITION (ISRCTN 72509687), which is testing a novel treatment approach for HIV-associated cryptococcal meningitis and is recruiting participants from multiple sites across sub-Saharan Africa.

The investigators will collect data from trial participants and their relatives who provided consent on their behalf in Gaborone, Botswana; Kampala, Uganda and Harare, Zimbabwe. Interviews will follow a narrative approach and encourage the drawing of timelines. This will be supplemented by direct observation of the research process at each of the three recruiting hospitals. In addition, interviews will take place with researchers from the African and European institutions that form the partnership through which the trial is administered. Findings from the interviews will be prospectively fed back to the individual sites and Trial Management Group to improve the ongoing trial.

Study Design

Study Type:
Observational
Actual Enrollment :
89 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
The Lived Experience of Participants in an African Randomised Trial
Actual Study Start Date :
Feb 5, 2020
Actual Primary Completion Date :
Jun 11, 2021
Actual Study Completion Date :
Jun 11, 2021

Arms and Interventions

Arm Intervention/Treatment
AMBITION Trial Participants

Individuals who have been enrolled into the AMBITION trial

Other: In-depth interviews
In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
Other Names:
  • Direct observation
  • The next-of-kin of AMBITION Trial Participants

    Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline

    Other: In-depth interviews
    In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
    Other Names:
  • Direct observation
  • AMBITION Researchers

    Individuals working on the AMBITION trial

    Other: In-depth interviews
    In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
    Other Names:
  • Direct observation
  • Outcome Measures

    Primary Outcome Measures

    1. Experience and views of individuals involved in the AMBITION trial [18 months]

      Interviews with AMBITION trial participants and their next-of-kin will be semi-structured and follow a loose interview guide that adopts a narrative approach to understand the experience of being diagnosed with HIV-associated cryptococcal meningitis, being approached and enrolling into the trial, undergoing invasive procedures, completing follow-up and then exiting the trial. Interviews will take place during and after the trial. Interviews with researchers will follow a thematic line of enquiry to understand how the trial can be improved for participants as well as how transnational research partnerships could be optimised for the benefit of researchers. Direct observations will help to contextualise the findings from the interviews by situating them within the clinical environment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    AMBITION Trial Participants

    Inclusion Criteria:
    • Enrolled onto the AMBITION trial and has completed at least six weeks of follow-up

    • Not currently confused

    • Willing and able to consent to the study

    Exclusion Criteria:
    • Nil

    The next-of-kin of AMBITION Trial Participants

    Inclusion Criteria:
    • Provided surrogate consent for an individual who was enrolled into the AMBITION trial

    • Willing and able to consent to the study

    Exclusion Criteria:
    • Nil

    AMBITION Researchers

    Inclusion Criteria:
    • Currently or previously employed on the AMBITION trial

    • Willing and able to consent to the study

    Exclusion Criteria:
    • Nil

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Botswana Harvard AIDS Institute Gaborone Botswana
    2 Infectious Diseases Institute, Uganda Kampala Uganda
    3 University of Zimbabwe Harare Zimbabwe

    Sponsors and Collaborators

    • London School of Hygiene and Tropical Medicine
    • Botswana Harvard AIDS Institute Partnership
    • Infectious Diseases Institute, Uganda
    • University of Zimbabwe

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    London School of Hygiene and Tropical Medicine
    ClinicalTrials.gov Identifier:
    NCT04296292
    Other Study ID Numbers:
    • 17957
    First Posted:
    Mar 5, 2020
    Last Update Posted:
    Apr 6, 2022
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2022